Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
DUBLIN, Ireland, Dec. 15, 2016 -- HiberGene Diagnostics, a company focussed on applying molecular technology to the infectious disease segment of the diagnostics market, has announced that it has CE marked its HG C. difficile test.
HG C. difficile enables the rapid and accurate detection of the bacterium, Clostridium difficile (C. difficile), from stool samples in under 60 minutes. C. difficile is the major cause of hospital-acquired diarrhoea which can be fatal, particularly in elderly and immuno-compromised patients. Furthermore, the highly infectious nature of the bacterium, coupled with its resistance to current standard cleaning methods, means it can spread quickly leading to serious outbreaks in healthcare facilities.
The launch of HG C. difficile is the third in HiberGene’s expanding portfolio of tests which includes Meningococcus and Group B Streptococcus. In addition, the utility of the Meningococcus and Group B Streptococcus was recently expanded with the inclusion of a direct swab capability.
Commonly-used test methods for C. difficile include time-consuming cell culture techniques and frequently insensitive enzyme assays. HiberGene’s highly sensitive and specific C. difficile test takes approximately an hour and can be performed outside the laboratory setting.
Brendan Farrell, CEO of HiberGene, said: “The launch of the HG C. difficile test will help in tackling the spread of C. difficile in clinical environments. The spread of C. difficile can cause significant ill health, despite its relative ease to tackle. However, the inability to provide a rapid, on the spot, diagnosis can often result in a delay in effective treatment being administered. By using the HG C. difficile test, health professionals can now quickly and easily diagnose the presence of the bacterium and provide an effective treatment.”
Notes to Editors:
About HiberGene
HiberGene is a diagnostics company focussed on applying molecular technology to the infectious disease segment of the diagnostic market. Utilising the LAMP platform, HiberGene has developed rapid and highly sensitive diagnostic tests for Meningococcus, Group B Streptococcus and C. difficile which can be used in almost any clinical or laboratory setting. HiberGene intends to continue to expand its test menu for the detection of human infectious diseases.
www.hibergene.com
For more information, please contact: Tony Stephenson Exitus Communications Tel: +44 (0)7899 796655 Email: [email protected] Brendan Farrell Chairman & CEO HiberGene Diagnostics Limited Email: [email protected]
